GU Cancers 2022 | Adjuvo: first randomized trial of adjuvant mitotane in adrenocortical carcinoma patients
Alfredo Berruti, MD, University of Brescia, Brescia, Italy, provides an overview of the Adjuvo study comparing the efficacy of adjuvant mitotane treatment versus observation on prolonging recurrence-free survival (RFS) in patients with adrenocortical carcinoma at low-intermediate risk of recurrence. Results do not support the routine use of adjuvant mitotane in this subset of patients, who may thus avoid a potentially toxic treatment. This interview took place at the American Society of Clinical Oncology (ASCO) Genitourinary Cancers Symposium 2022 in San Francisco, CA.
Transcript (edited for clarity)
This was an academic-based prospective randomized clinical trial, which tests the efficacy of mitotane administered in adjuvant setting in patients with adrenocortical carcinoma that were radically operated and were at low-intermediate risk of relapse.
This was an academic-based prospective randomized clinical trial, which tests the efficacy of mitotane administered in adjuvant setting in patients with adrenocortical carcinoma that were radically operated and were at low-intermediate risk of relapse.
Read more...
